ANI Pharmaceuticals (NASDAQ:ANIP) Sees Large Volume Increase

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw unusually-strong trading volume on Thursday . Approximately 104,682 shares traded hands during trading, a decline of 47% from the previous session’s volume of 198,529 shares.The stock last traded at $54.87 and had previously closed at $54.32.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of recent analyst reports. Truist Financial reaffirmed a “hold” rating and set a $60.00 price target (down from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.75.

ANI Pharmaceuticals Stock Up 4.2 %

The stock has a 50 day moving average of $61.45 and a 200 day moving average of $63.89. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of 36.57 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same period in the previous year, the business earned $1.06 EPS. The business’s quarterly revenue was up 18.5% on a year-over-year basis. As a group, analysts expect that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current fiscal year.

Insider Activity

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total value of $900,472.12. Following the sale, the chief operating officer now directly owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the sale, the chief operating officer now owns 635,363 shares of the company’s stock, valued at approximately $40,129,527.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Chad Gassert sold 20,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the transaction, the senior vice president now owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The disclosure for this sale can be found here. In the last three months, insiders sold 65,757 shares of company stock valued at $4,075,585. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in ANIP. Innealta Capital LLC acquired a new stake in shares of ANI Pharmaceuticals during the second quarter worth $65,000. Ridgewood Investments LLC acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $85,000. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals during the first quarter valued at about $106,000. ADAR1 Capital Management LLC acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter worth about $132,000. Finally, Clear Street Markets LLC purchased a new position in shares of ANI Pharmaceuticals in the fourth quarter worth approximately $140,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.